NASDAQ:TRVI

Trevi Therapeutics Stock Predictions

etoro logo Buy TRVI
*Your capital is at risk
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

TRVI Prediction Chart

TRVI Predictions History

Latest community submissions for TRVI.
Predictor Target Session Target Price Result Direction Accuracy Score
Mar 5, 2026 Bullish $13.08 V 1
Feb 11, 2026 $11.53 +2.52% $11.05 X 95.62% 0
Feb 11, 2026 $11.07 -1.57% $11.05 V 99.79% 6
Feb 11, 2026 Bullish $11.05 X 0
Oct 16, 2025 $10.39 -2.18% $10.63 X 97.73% 0
Oct 16, 2025 $10.48 -1.36% $10.63 X 98.54% 1
Oct 16, 2025 Bullish $10.63 V 1
Oct 16, 2025 Bullish $10.63 V 1
Sep 15, 2025 $8.51 +3.17% $8.07 X 94.46% 0
Sep 15, 2025 $8.09 -1.98% $8.07 V 99.74% 5
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for TRVI with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT TREVI THERAPEUTICS INC.
Trevi Therapeutics
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE